% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • thirdmeinvestor thirdmeinvestor Apr 26, 2008 12:26 PM Flag

    Schering-Plough News Release

    Good work, Michael. The essence is contained in the paragraph:

    In a 28-week treatment regimen in which patients received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID), the rate of sustained virological response at 12 weeks after the end of treatment (SVR 12) was 57 percent (ITT).(1-3) Importantly, this treatment regimen provided an indication of early predictability of response, with patients who had undetectable virus (HCV-RNA) in plasma after 4 weeks of boceprevir treatment achieving an SVR 12 rate of 86 percent.


    The 4wk + 24wk arm has an SVR(12wk)of 57%, and patient achieving an RVR have a chance of 86%. All inferior to PROVE 1 OR 2 results

    SortNewest  |  Oldest  |  Most Replied Expand all replies
126.53-2.47(-1.91%)Sep 3 4:00 PMEDT